Clinical Trials
61 trialsA Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Amgen
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
PRESERVE-009
OncoC4, Inc.
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM, LLC (dba US WorldMeds)
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
ARC-12
Arcus Biosciences, Inc.
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
AM-003
University of Virginia
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
PDL1x41BB
Inhibrx Biosciences, Inc
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
DUET-3
Xencor, Inc.
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
TORCH
University of Florida
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
DUET-4
Xencor, Inc.
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
GEN602
Genzada Pharmaceuticals USA, Inc.
DUET-2
Xencor, Inc.
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
A Safety Study of SGN-CD47M in Patients With Solid Tumors
Seagen Inc.
MK-6018-001
KitovPharma
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Roswell Park Cancer Institute
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey